Answers are grounded in this paper and cite their sources.
INTRODUCTION: Protein kinase A (PKA) is a central mediator of cyclic adenosine monophosphate (cAMP) signaling. Its brain-enriched regulatory subunit RIβ, encoded by PRKAR1B, is implicated in neurodevelopmental and neurodegenerative diseases. AREAS COVERED: This Special Report integrates structural, biochemical, genetic, and disease-model evidence linking RIβ domain dysfunction to human phenotypes. Marbach-Schaaf neurodevelopmental syndrome (MASNS) variants cluster mainly in cyclic nucleotide-binding (CNB) domains; R335W forms a cAMP-insensitive, dominant-negative holoenzyme that sequesters the catalytic subunit in a heterologous cellular system. For L50R, loss of RIβ homodimerization and tetrameric assembly generates an aggregation-prone subunit. RIβ aggregation and neuronal loss in affected human brain and L50R knock-in mice support abnormal self-association and aggregation as a central pathogenic mechanism in neuronal loss and parkinsonism driven by a PKA mutation (NLPD-PKA). We discuss domain-function-phenotype relationships and mechanism-guided therapeutic strategies. EXPERT OPINION: Mechanistic understanding differs between PRKAR1B-associated disorders. L50R produces context-dependent abnormalities in cAMP regulation and catalytic-subunit behavior, reflecting distinct mutant physical states rather than an established sequence of events. R335W impairs cAMP-dependent catalytic-subunit release and alters RIβ condensate behavior, but mechanisms of most MASNS variants remain unresolved, and the R335W findings should not be generalized across the disorder. Variant-specific functional classification is essential for developing mechanism-guided therapies.
No takes yet. Share an insight, caveat, or question.
Boutros‐Suleiman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: